source
- Boehringer Ingelheim to seek approval for obesity injection survodutide after trial shows no added cardiovascular riskBoehringer Ingelheim announced it will file for regulatory approval of its investigational GLP-1 based obesity injection, survodutide, in the coming year. The move follows a phase 3 trial that dem…
- Eli Lilly to pursue FDA approval for obesity drug in obstructive sleep apnea after positive Phase 3 trialEli Lilly announced that it will seek regulatory approval for its obesity medication as a treatment for obstructive sleep apnea, following a successful Phase 3 study. The trial showed positive res…